AbbVie’s ABBV-295 Yields 7.75%-9.79% Weight Loss in Phase 1 Trial
AbbVie’s ABBV-295 obesity drug achieved mean weight reductions of 7.75% to 9.79% at week 12 across 2-14 mg dosing in a Phase 1 study. AbbVie represents 6.57% of the IYH ETF, so strong ABBV stock performance could lift ETF returns.
1. Phase 1 Trial Results
AbbVie reported that ABBV-295 produced dose-dependent mean body-weight reductions ranging from 7.75% to 9.79% at week 12 in its Phase 1 obesity study. Results reflect consistent efficacy across multiple dosing cohorts, with the highest doses delivering nearly 10% weight loss over three months.
2. Safety and Dosing
The study evaluated ABBV-295 at doses between 2 mg and 14 mg, with participants generally tolerating the treatment well. Mild gastrointestinal disorders were the most common adverse events, and no severe safety signals emerged during the 12-week trial period.
3. ETF Exposure and Market Context
AbbVie accounts for 6.57% of the IYH ETF’s holdings, positioning the ETF to benefit from positive drug developments. AbbVie shares trade slightly above their 20-day and 100-day averages, while the Healthcare sector remains one of the better-performing groups despite modest market declines.